Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study

Fortea, Adriana; Ilzarbe, Daniel; Espinosa, Laura; Solerdelcoll, Mireia; Castro, Clara de; Oriolo, Giovanni; Sugranyes, Gisela; Baeza, Inmaculada

doi:10.1089/cap.2017.0096

Cited by 24 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mean improvement of 31.7 (SD = 8.7) between admission and discharge was observed on the Children's Global Assessment Scale (CGAS); no differences were found between the different LAIs. Although they were generally well tolerated, 23.3% of patients reported mild short-term side effects, which were more frequent with risperidone than with aripiprazole (p = 0.014) (82).…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Giordano¹,

Tomassini²,

Cuomo

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once monthly (AOM) in the treatment of FEP in patients aged 18-26 years. Methods: We included 50 patients with DSM-5 schizophrenia as assessed with SCID, and used the Clinical Global Impressions Scale-Severity of Illness (CGI-S) and the Positive and Negative Syndrome Scale (PANSS) to assess symptom severity and the World Health Organization Quality of Life (WHOQOL), the Short Form Health Survey (SF-36) and the Personal and Social Performance Scale (PSP) to assess quality of life (QoL) and global health perception at baseline and 3, 6, 9, and 12 months after the first AOM injection. Results: AOM was associated with a progressive improvement, compared to baseline, of both positive (p < 0.001) and negative (p < 0.001) symptoms and in general psychopathology (p < 0.001) and decrease in global severity (p < 0.001). We also observed progressive improvement in QoL and social and personal functioning. Treatment adherence was 78% at study endpoint. Our results support that AOM may improve psychotic symptoms, QoL and social functioning in young FEP patients. Further studies should compare AOM to its oral formulation in the treatment of young patients with schizophrenia at the outset of their illness.

show abstract

Section: Discussionmentioning

confidence: 93%

“…An observational retrospective study (82) focused on the use of second-generation LAIs in adolescence. The use of risperidone (36.7%), aripiprazole (40%), and paliperidone palmitate (23.3%) LAI was mainly based on a history of low compliance (90%) and/ or poor insight (73.3%).…”

Section: Discussionmentioning

confidence: 99%

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Giordano¹,

Tomassini²,

Cuomo

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…We propose that LAI‐AP should be introduced as early as possible in FEP‐SUD subjects, since this population represents a great challenge for treatment adherence and response. Further studies will be necessary to fully understand the clinical, functional and pharmacoeconomical impacts of this strategy, as some recent studies have already shown in general cohorts (Collins et al, ; Fortea et al, ; Lefebvre et al, ; Stip & Lachaine, ).…”

Section: Resultsmentioning

confidence: 99%

Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder

Abdel‐Baki

Thibault

Medrano

et al. 2019

Early Intervention Psych

View full text Add to dashboard Cite

Aim: Substance use disorder (SUD) is highly prevalent among patients with firstepisode psychosis (FEP) and associated with poor adherence and worst treatment outcomes. Although relapses are frequent in FEP, current literature on long-acting injectable antipsychotics (LAI-AP) use in FEP is scarce and studies often exclude patients with SUD. Objectives: To determine the impact of LAI-AP as first-line treatment on psychotic relapses or rehospitalizations in FEP patients with comorbid SUD (FEP-SUD). Methods: This is a naturalistic, longitudinal, 3-year prospective and retrospective study on 237 FEP-SUD admitted in two EIS in Montreal, between 2005 and 2012. The patients were divided on the basis of first-line medication introduced, either oral antipsychotics (OAP, n = 206) or LAI-AP (n = 31). Baseline characteristics were compared using χ² test and analysis of variance, and Kaplan-Meier survival analysis was performed on relapse and rehospitalization. Results: Compared to the OAP group, patients in the LAI-AP group presented worse prognostic factors (eg, history of homelessness). Despite this, the LAI-AP group presented a lower relapse rate (67.7% vs 76.7%), higher relapse-free survival time (694 vs 447 days, P = 0.008 in Kaplan-Meier analysis), and trends for reduced rehospitalization rates (48.4% vs 57.3%) and hospitalization-free survival time (813 vs 619 days, P = 0.065 Kaplan-Meier analysis). Of those receiving OAP as firstline, 41.3% were eventually switched to LAI-AP and displayed worst outcome in relapse and rehospitalization. Conclusion: LAI-AP should be strongly considered as first-line treatment of FEP-SUD patients since this pharmacological option reduces the risk of relapse and rehospitalization even in the individuals with poor prognostic factors. K E Y W O R D S first-episode psychosis, hospitalization, long-acting antipsychotic, relapse, substance use disorder

show abstract

“…Long-acting injectable antipsychotics (LAIAs) may provide an ideal solution to this problem. A recent observational study of LAIAs (specifically: aripiprazole, risperidone, and paliperidone) in hospitalized adolescents with mental illness suggest that LAIAs are well tolerated and associated with improvements in the Children's Global Assessment Scale (CGAS) (Fortea et al, 2018). While there are no studies looking at LAIAs in youth with ASD specifically, outside of a single case report (Kowalski et al, 2011), work in other psychiatric disorders such as schizophrenia suggest that they are safe and well tolerated, with similar side effect profiles to oral medications.…”

Section: Long Acting Injectable Antipsychoticsmentioning

confidence: 99%

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Henneberry

Lamy

Dominick

et al. 2021

J Autism Dev Disord

View full text Add to dashboard Cite

Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field.

show abstract

Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study

Cited by 24 publications

References 45 publications

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Contact Info

Product

Resources

About